|
1
|
Smith DC and Pienta KJ: Paclitaxel in the
treatment of hormone-refractory prostate cancer. Semin Oncol. 26 (1
Suppl 2):S109–S111. 1999.
|
|
2
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakayama S, Torikoshi Y, Takahashi T,
Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K,
Hortobagyi GN, et al: Prediction of paclitaxel sensitivity by CDK1
and CDK2 activity in human breast cancer cells. Breast Cancer Res.
11:R122009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by Taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang LG, Liu XM, Kreis W and Budman DR:
The effect of antimicrotubule agents on signal transduction
pathways of apoptosis: A review. Cancer Chemother Pharmacol.
44:355–361. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gan L, Wang J, Xu H and Yang X: Resistance
to docetaxel-induced apoptosis in prostate cancer cells by
p38/p53/p21 signaling. Prostate. 71:1158–1166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann N Y Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng DJ, Wang J, Zhou JY and Wu GS: Role
of the Akt/mTOR survival pathway in cisplatin resistance in ovarian
cancer cells. Biochem Biophys Res Commun. 394:600–605. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou
J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene
PTEN on the resistance to cisplatin in human ovarian cancer cell
lines and related mechanisms. Cancer Lett. 271:260–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramaswamy S, Nakamura N, Vazquez F, Batt
DB, Perera S, Roberts TM and Sellers WR: Regulation of G1
progression by the PTEN tumor suppressor protein is linked to
inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc
Natl Acad Sci USA. 96:2110–2115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang R, Banika NL and Rayb SK:
Differential sensitivity of human glioblastoma LN18 (PTEN-positive)
and A172 (PTEN-negative) cells to Taxol for apoptosis. Brain Res.
1239:216–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bilani N, Bahmad H and Abou-Kheir W:
Prostate cancer and aspirin use: Synopsis of the proposed molecular
mechanisms. Front Pharmacol. 8:1452017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Debes JD and Tindall DJ: Mechanisms of
androgen refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cairns P, Okami K, Halachmi S, Halachmi N,
Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS and Sidransky D:
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cancer Res. 57:4997–5000. 1997.PubMed/NCBI
|
|
17
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: The PI3K pathways as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leslie NR and Downes CP: PTEN function:
How normal cells control it and tumour cells lose it. Biochem J.
382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Z, Pore N, Cerniglia GJ, Mick R,
Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK and Maity A:
Phosphatase and tensin homologue deficiency in glioblastoma confers
resistance to radiation and temozolomide that is reversed by the
protease inhibitor nelfinavir. Cancer Res. 67:4467–4473. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang M, Volpert O, Shi YH and Bouck N:
Maspin is an angiogenesis inhibitor. Nat Med. 6:196–199. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marioni G, Koussis H, Gaio E, Giacomelli
L, Bertolin A, D'Alessandro E, Scola A, Ottaviano G, de Filippis C,
Jirillo A, et al: MASPIN's prognostic role in patients with
advanced head and neck carcinoma treated with primary chemotherapy
(carboplatin plus vinorelbine) and radiotherapy: Preliminary
evidence. Acta Otolaryngol. 129:786–792. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klasa-Mazurkiewicz D, Narkiewicz J,
Milczek T, Lipińska B and Emerich J: Maspin overexpression
correlates with positive response to primary chemotherapy in
ovarian cancer patients. Gynecol Oncol. 113:91–98. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou Z, Gao C, Nagaich AK, Connell T, Saito
S, Moul JW, Seth P, Appella E and Srivastava S: p53 regulates the
expression of the tumor suppressor gene maspin. J Biol Chem.
275:6051–6054. 2000. View Article : Google Scholar : PubMed/NCBI
|
